硫唑嘌呤治疗免疫相关性皮肤病专家建议

doi:10.35541/cjd.20200469

Abstract

Abstract: 【Abstract】 Azathioprine, an imidazole derivative of mercaptopurine, has been widely used in the treatment of autoimmune diseases. In order to standardize the application of azathioprine in dermatology, relevant experts in the Committee on Autoimmune Diseases of China Dermatologist Association searched and studied domestic and foreign literature on azathioprine for the treatment of immune-related diseases （mainly including randomized control trials, expert consensus or proposals）, and proposed a proposal after repeated discussions for azathioprine in the treatment of immune skin diseases, including immune bullous skin diseases, cutaneous vasculitis, systemic lupus erythematosus, dermatomyositis, scleroderma, etc. Interactions between azathioprine and other drugs, as well as issues needed to be considered in its application were also analyzed in this proposal.

Key words: Azathioprine, Therapy, Autoimmune diseases, Connective tissue diseases, Pemphigus, Lupus erythematosus, systemic, Dermatomyositis

Committee on Autoimmune Diseases, China Dermatologist Association. Azathioprine in the treatment of immune?related skin diseases: an expert proposal[J]. Chinese Journal of Dermatology, 2021, 54(2): 116-121.doi:10.35541/cjd.20200469

References ［37］

［1］	Wollenberg A, Szepietowski J, Taieb A, et al. Corrigendum: Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part I［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1436. doi: 10.1111/jdv.15719.
［2］	Paek SY, Lim HW. Chronic actinic dermatitis［J］. Dermatol Clin,2014,32（3）:355⁃361, viii⁃ix. doi: 10.1016/j.det.2014.03.007.
［3］	Verma P, Verma KK, Khanna N, et al. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open⁃label study［J］. Clin Exp Dermatol, 2016,41（7）:717⁃722. doi: 10.1111/ced.12887.
［4］	Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review［J］. Eur J Dermatol, 2019,29（5）:524⁃537. doi: 10.1684/ejd.2019.3641.
［5］	Tal Y, Toker O, Agmon⁃Levin N, et al. Azathioprine as a therapeutic alternative for refractory chronic urticaria［J］. Int J Dermatol, 2015,54（3）:367⁃369. doi: 10.1111/ijd.12536.
［6］	Relling MV, Schwab M, Whirl⁃Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update［J］. Clin Pharmacol Ther, 2019,105（5）:1095⁃1105. doi: 10.1002/cpt.1304.
［7］	Rucci F, Cigoli MS, Marini V, et al. Combined evaluation of genotype and phenotype of thiopurine S⁃methyltransferase （TPMT） in the clinical management of patients in chronic therapy with azathioprine［J/OL］. Drug Metab Pers Ther, 2019,34（1）［2020⁃03⁃19］. http://www.metstr.com. doi: 10.1515/dmpt⁃2018⁃0037.
［8］	Wilson A, Jansen LE, Rose RV, et al. HLA⁃DQA1⁃HLA⁃DRB1 polymorphism is a major predictor of azathioprine⁃induced pancreatitis in patients with inflammatory bowel disease［J］. Aliment Pharmacol Ther, 2018,47（5）:615⁃620. doi: 10.1111/apt. 14483.
［9］	Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines［J］. BMJ, 2001,323（7308）:334⁃336. doi: 10.1136/bmj.323.7308.334.
［10］	Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2015,29（3）:405⁃414. doi: 10.1111/jdv. 12772.
［11］	Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphigus［J］. J Dermatol, 2014,41（6）:471⁃486. doi: 10.1111/1346⁃8138.12486.
［12］	Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 1 ⁃ current therapies［J］. Expert Rev Clin Immunol, 2019,15（10）:1047⁃1060. doi: 10.1080/1744666X.2020.1672535.
［13］	Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone［J］. Br J Dermatol, 2017,177（5）:1299⁃1305. doi: 10.1111/bjd.15649.
［14］	Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology［J］. Br J Dermatol, 2015,172（4）:867⁃877. doi: 10. 1111/bjd.13717.
［15］	Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:20⁃32. doi: 10.1590/abd1806⁃ 4841.2019940206.
［16］	Yoshida A, Watanabe M, Okubo A, et al. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases （anti⁃neutrophil cytoplasmic antibody⁃associated vasculitis and rheumatoid arthritis）［J］. Jpn J Ophthalmol, 2019,63（5）:417⁃424. doi: 10.1007/s10384⁃019⁃00674⁃7.
［17］	中国狼疮肾炎诊断和治疗指南编写组. 中国狼疮肾炎诊断和治疗指南［J］. 中华医学杂志, 2019,99（44）:3441⁃3455. doi: 10.3760/cma.j.issn.0376⁃2491.2019.44.001.
［18］	Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association （EULAR/ERA⁃EDTA） recommendations for the management of adult and paediatric lupus nephritis［J］. Ann Rheum Dis, 2012,71（11）:1771⁃1782. doi: 10.1136/annrheumdis⁃2012⁃201940.
［19］	Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis［J］. J Am Soc Nephrol, 2016,27（10）:2929⁃2939. doi: 10.1681/ASN.2016040415.
［20］	Ordi⁃Ros J, Sáez⁃Comet L, Pérez⁃Conesa M, et al. Enteric⁃coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial［J］. Ann Rheum Dis, 2017,76（9）:1575⁃1582. doi: 10.1136/annrheumdis⁃2016⁃210882.
［21］	Pons⁃Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus （GLADEL, Grupo Latino Americano de Estudio del Lupus）⁃Pan⁃American League of Associations of Rheumatology （PANLAR）［J］. Ann Rheum Dis, 2018,77（11）:1549⁃1557. doi: 10.1136/annrheumdis⁃2018⁃213512.
［22］	Tamirou F, D′Cruz D, Sangle S, et al. Long⁃term follow⁃up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis［J］. Ann Rheum Dis, 2016,75（3）:526⁃531. doi: 10.1136/annrheumdis⁃2014⁃206897.
［23］	Dalakas MC. Inflammatory myopathies: management of steroid resistance［J］. Curr Opin Neurol, 2011,24（5）:457⁃462. doi: 10. 1097/WCO.0b013e32834a9589.
［24］	Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists［J］. J Dermatol, 2019,46（1）:e1⁃e18. doi: 10.1111/1346⁃8138.14604.
［25］	中华医学会儿科学分会免疫学组, 《中华儿科杂志》编辑委员会, 胡坚. 幼年皮肌炎诊治建议［J］. 中华儿科杂志, 2012,50（8）:617⁃621. doi: 10.3760/cma.j.issn.0578⁃1310.2012.08.013.
［26］	Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open⁃label study［J］. J Rheumatol, 2008,35（6）:1064⁃1072.
［27］	Iudici M, Cuomo G, Vettori S, et al. Low⁃dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis （SSc⁃ILD）: efficacy of maintenance immunosuppression in responders and non⁃responders［J］. Semin Arthritis Rheum, 2015, 44（4）:437⁃444. doi: 10.1016/j.semarthrit.2014.09.003.
［28］	Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema［J］. J Allergy Clin Immunol, 2011,128（2）:353⁃359. doi: 10. 1016/j.jaci.2011.03.024.
［29］	Sarika S, Criton S. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open⁃label study: reply to author［J］. Clin Exp Dermatol, 2017,42（7）:805⁃806. doi: 10.1111/ced.13193.
［30］	Solman L, Lloyd⁃Lavery A, Grindlay DJC, et al. What′s new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention［J］. Clin Exp Dermatol, 2019,44（4）:363⁃369. doi:10.1111/ced.13885.
［31］	Paek SY, Lim HW. Chronic actinic dermatitis［J］. Dermatol Clin, 2014,32（3）:355⁃361, viii⁃ix. doi: 10.1016/j.det.2014.03.007.
［32］	Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. J Dtsch Dermatol Ges, 2016,14（3）:321⁃338. doi: 10.1111/ddg.12909.
［33］	Mathur T, Manadan AM, Thiagarajan S, et al. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy［J］. Am J Ther, 2015,22（5）:350⁃354. doi: 10.1097/MJT.0b013e3182987983.
［34］	Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther, 2011,89（3）:387⁃391. doi: 10.1038/clpt. 2010.320.
［35］	Yang J, Wang P, Qin Z, et al. NUDT15 and TPMT genetic polymorphisms are related to azathioprine intolerance in Chinese patients with rheumatic diseases［J］. Genet Test Mol Biomarkers, 2019,23（10）:751⁃757. doi: 10.1089/gtmb.2018.0313.
［36］	Kim HT, Choi R, Won HH, et al. NUDT15 genotype distributions in the Korean population［J］. Pharmacogenet Genomics, 2017,27（5）:197⁃200. doi: 10.1097/FPC.000000000 0000274.
［37］	Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6⁃MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia［J］. Br J Haematol, 2015, 171（1）:109⁃115. doi: 10.1111/bjh.13518.

[1]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767.
[2]	Lyu Ling, Lyu Xiaoyan. Dermatomyositis with malignancy: an update [J]. Chinese Journal of Dermatology, 2022, 55(3): 276-279.
[3]	Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212.
[4]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[5]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694.
[6]	Wang Yanyan, Wang Xiaoju, Wang Yuhuan, Gu Tianming, Ding Jiashuo. Identification of core contents of health education for patients with pemphigus by using the Delphi method [J]. Chinese Journal of Dermatology, 2022, 0(2): 20201120-e20201120.
[7]	Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631.
[8]	Huang Yaxin, He Yuanmin, Huang Shuli, Xiong Xia, Deng Yongqiong. An investigation into clinical significance of serum chitinase 3-like protein 1 in pemphigus vulgaris [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210155-e20210155.
[9]	Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384.
[10]	Hu Feng, Wang Xiangdong, Xia Yun, Zhou Xiaoyong, Chen Liuqing. Pemphigus foliaceus converting into bullous pemphigoid: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(2): 156-158.
[11]	Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184.
[12]	Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156.
[13]	Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64.
[14]	Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19.
[15]	Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases （2022） [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11.

Azathioprine in the treatment of immune?related skin diseases: an expert proposal

PDF

Knowledge

Abstract

Cite this article

share this article

References ［37］

Related Articles 15

Metrics

Comments

Recommended 10